Showing results (2091-2100 of 2,589) with videos related to

Sort By:
Pageof 259
Molecular Oncology|December 2, 2021
Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitorsXiang Cheng, Bin Zhang, Feng Guo, et al.
Molecular Oncology|December 2, 2021
Precision N-glycoproteomics reveals elevated LacdiNAc as a novel signature of intrahepatic cholangiocarcinomaJun Li, Ting Zhao, Jing Li, et al.
Molecular Oncology|December 2, 2021
Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatmentJohn C Dawson, Alison Munro, Kenneth Macleod, et al.
Molecular Oncology|December 3, 2021
Anti-Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibition of M2 polarizationJi Eun Yu, In Jun Yeo, Dong Ju Son, et al.
Molecular Oncology|December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detectionAndi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
Molecular Oncology|February 19, 2021
Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinomaRory M Bade, Jennifer L Schehr, Hamid Emamekhoo, et al.
Molecular Oncology|February 19, 2021
Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinomaTomohiro Murakami, Yoshiaki Shoji, Tomohiko Nishi, et al.
Molecular Oncology|September 24, 2019
Klotho-mediated targeting of CCL2 suppresses the induction of colorectal cancer progression by stromal cell senescent microenvironmentsYangyang Liu, Jie Pan, Xia Pan, et al.
Molecular Oncology|January 15, 2021
Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patientsXinyu Ji, Lijuan Lin, Sipeng Shen, et al.
Molecular Oncology|February 7, 2017
Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cellsPeng Han, Hali Li, Xian Jiang, et al.
Pageof 259